Biohaven Ltd. Common Shares (BHVN)
BHVN moved a median of -0.27% 30 minutes after news, and -0.61% by the close. How BHVN actually reacts to news — the realized, point-in-time move the market made, measured across 944 labeled events over the last three years with zero look-ahead.
BHVN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 51% | 941 |
| 30-min | -0.27% | 45% | 942 |
| 60-min | -0.29% | 39% | 942 |
| to close | -0.61% | 40% | 910 |
| Middle 50% of BHVN reactions | -1.10% to +0.95% |
|---|---|
| Median reaction (30-min) | -0.27% |
| Measured reactions | 944 |
Half of all Biohaven Ltd. Common Shares news events land between -1.10% and +0.95% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BHVN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 22 | +0.35% | 64% | +2.43% |
| Coverage initiations | 35 | +1.52% | 74% | +1.06% |
| Rating reiterations | 115 | +0.05% | 52% | -0.23% |
| Price-target raises | 18 | -0.09% | 44% | -1.20% |
| Price-target cuts | 20 | -0.10% | 45% | +0.64% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how BHVN ranks against every other measured name →
That’s how BHVN usually reacts — get an email when it moves on news →Email me when BHVN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BHVN's baseline. Nothing else.
Recent BHVN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Biohaven Ltd. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -4.69% | |
| Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease | Press release | PR Newswire | -1.90% | +0.84% | |
| Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 | Press release | PR Newswire | +0.41% | +3.51% | |
| Form 8-K Biohaven Ltd. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -4.34% | |
| Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy | Press release | PR Newswire | -3.19% | +22.91% | |
| Form 8-K Biohaven Ltd. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -3.19% | +22.91% | |
| Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University | Press release | PR Newswire | -3.19% | +22.91% | |
| Form 8-K Biohaven Ltd. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | — | |
| Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors | Press release | PR Newswire | +0.59% | +5.95% | |
| Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million | Press release | PR Newswire | +0.11% | -1.09% | |
| Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload | Press release | PR Newswire | +0.23% | -4.19% | |
| Biohaven Announces Scientific Leadership Transitions | Press release | PR Newswire | -1.16% | -4.89% | |
| Form 8-K Biohaven Ltd. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | -4.89% | |
| Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator | Press release | PR Newswire | +1.15% | +0.88% | |
| Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease | Press release | PR Newswire | +3.14% | +4.33% | |
| Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation | Press release | PR Newswire | -2.20% | +3.07% | |
| Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy | Press release | PR Newswire | -1.88% | +11.12% | |
| Form 8-K Biohaven Ltd. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | -7.91% | |
| Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile | Press release | PR Newswire | +2.68% | +6.00% | |
| Form 8-K Biohaven Ltd. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | +2.55% | |
| Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results | Press release | PR Newswire | +5.47% | -4.33% | |
| Form 10-Q Biohaven Ltd. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.47% | -4.33% | |
| Form 8-K Biohaven Ltd. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +5.47% | -4.33% | |
| Form 8-K Biohaven Ltd. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +5.47% | -4.33% | |
| Form S-3ASR Biohaven Ltd. | SEC filing · Form S-3ASR | SEC EDGAR | +5.47% | -4.33% | |
| Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment | Press release | PR Newswire | -0.44% | -0.89% | |
| Form DEF 14A Biohaven Ltd. For: Apr 28 | SEC filing · Form DEF | SEC EDGAR | -0.51% | -0.93% | |
| Form DEFA14A Biohaven Ltd. | SEC filing · Form DEFA14A | SEC EDGAR | -0.51% | -0.93% | |
| Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Press release | PR Newswire | -2.90% | -7.46% | |
| Form 10-K Biohaven Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.90% | -7.46% | |
| Form 8-K Biohaven Ltd. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -2.90% | -7.46% | |
| Form S-8 Biohaven Ltd. | SEC filing · Form S-8 | SEC EDGAR | -2.90% | -7.46% | |
| Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -0.55% | +7.93% | |
| Form 8-K Biohaven Ltd. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | +6.28% | |
| Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 | Press release | PR Newswire | +2.58% | +21.28% | |
| Form 8-K Biohaven Ltd. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +2.58% | +21.28% | |
| Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder | Press release | PR Newswire | — | +0.00% | |
| Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress | Press release | PR Newswire | +3.20% | +6.12% | |
| Biohaven Announces Pricing of $175 Million Public Offering of Common Shares | Press release | PR Newswire | +2.52% | +0.25% | |
| Biohaven Announces Proposed Public Offering of Common Shares | Press release | PR Newswire | +2.52% | +0.25% | |
| Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments | Press release | PR Newswire | -1.62% | -7.81% | |
| Form 10-Q Biohaven Ltd. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.62% | -7.81% | |
| Form 8-K Biohaven Ltd. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -7.81% | |
| FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia | Press release | PR Newswire | +8.86% | -0.12% | |
| Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN | Press release | Business Wire | -0.56% | +0.06% | |
| Form 8-K Biohaven Ltd. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -3.20% | -2.44% | |
| Form 8-K Biohaven Ltd. For: Aug 15 | SEC filing · Form 8-K | SEC EDGAR | +2.36% | +3.42% | |
| Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments | Press release | PR Newswire | -6.71% | -6.22% | |
| Form 10-Q Biohaven Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.66% | — | |
| Form 8-K Biohaven Ltd. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BHVN section they belong to.
Where else BHVN is measured.
BHVN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Intellia Therapeutics, Inc. (NTLA) | 948 | -0.24% | 45% |
| GW PHARMACEUTICALS PLC AMERICA (GWPH) | 942 | -0.06% | 47% |
| Intersect ENT, Inc. (XENT) | 937 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Biohaven Ltd. Common Shares's median reaction calculated?
Every labeled BHVN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 944 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of BHVN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BHVN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.